Search results
Sep 13, 2024 · Lenalidomide, bortezomib, and dexamethasone (RVd) have previously been established as standard-of-care induction therapy for newly diagnosed multiple myeloma (NDMM).
Sep 6, 2024 · Treatment directed at the underlying plasma cell clone is required to prevent complications and improve overall survival. MM must be distinguished from the premalignant stages of myeloma, namely monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM) (table 1 and algorithm 1).
4 days ago · FDA Approves Isa-RVd, a New Myeloma Combo Therapy. On Sept. 20, the U.S. Food and Drug Administration (FDA) approved a new combination therapy for adults with newly diagnosed multiple myeloma who are ineligible for stem cell transplants. The treatment is called Isa-VRd, which stands for isatuximab-irfc (Sarclisa) in combination with bortezomib ...
Sep 13, 2024 · Dara-VTD and RVD are beneficial for multiple myeloma patients eligible for autologous HSCT, with a trend favoring Dara-VTD in PFS, according to a study presented at SOHO 2024.
Sep 13, 2024 · Lenalidomide, bortezomib, and dexamethasone (RVd) have previously been established as standard-of-care induction therapy for newly diagnosed multiple myeloma (NDMM). More recently, randomized phase 3 data have demonstrated the benefit of the addition of daratumumab (Dara-RVd) to the RVd backbone in ….
6 days ago · The most anticipated DARZALEX quadruplet regimen (D-RVd) is undergoing evaluation for treating newly diagnosed multiple myeloma in transplant-eligible and ineligible patients. The evaluation of this treatment regimen will continue as part of the registrational, Phase III PERSEUS, and CEPHEUS study.
Sep 6, 2024 · CAR T-cell therapy is an emerging treatment that utilizes a patient’s engineered T-cells to target specific over-expressed proteins on the surface of MM cells. Its success has been indicated across numerous studies, as well as in real-world clinical practice.
